Biotech and Pharma

Each of the Magnificent Seven megacap stocks tumble as investors fret over President Donald Trump’s tariff threats.

Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.

GE Vernova rises after President Donald Trump and governors in the mid-Atlantic region unveil a plan to encourage the construction of power plants.

Britain’s regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.

The shares have climbed on every trading day so far in 2026. The streak looks set to continue.

Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.

A look at the chart suggests that momentum is on its side.

Wall Street is split on the stock, and the shares are close to the average price target. Something's got to give.

The pharma company has agreed to cut some prices in exchange for an exemption from some levies.

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.

Monday is the first day of J.P. Morgan’s annual healthcare investor conference.

Moderna’s 2028 cash breakeven guidance may not be feasible, analysts say.

The company‘s 2026 guidance and targets for 2027 and beyond should give investors a bit more cause for optimism. 

Vistra and Oklo stocks surge following agreements to provide nuclear power to Meta’s data centers.

Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.

Trump administration secures deal with Johnson & Johnson to reduce price of some medicines

Lockheed Martin and Northrop Grumman rally after President Donald Trump says he would hike the defense budget to $1.5 trillion next year.

The mineral-rich island is also strategically well-located, but acquiring it may be more trouble than it’s worth.

Shareholders in both drugmakers appear disappointed that a deal may not happen.

Shares of Western Digital and Seagate Technology Holdings fall after racking up dazzling gains in the previous session.

BofA Securities upgrades shares to Buy from Hold with an $860 price target, up sharply from $627.

Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.

Nvidia’s next major AI chip in full production, gold, silver prices rise, Novo Nordisk starts new front in weight-loss drug fight, and more news to start your day.

Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.

The company appears to have gotten the jump on Eli Lilly with what could be an important evolution in the market.